16 September 2021 
EMA/CHMP/504133/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Byannli2 
paliperidone 
On 16 September 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Paliperidone Janssen-Cilag International, which will now be known as Byannli. The marketing 
authorisation holder for this medicinal product is Janssen-Cilag International N.V.. 
Byannli will be available as prolonged-release suspension for injection (700 or 1,000 mg) for 6-monthly 
administration. The active substance of Byannli is paliperidone, a psycholeptic antipsychotic (ATC code: 
N05AX13). 
The full indication is: 
Byannli, a 6-monthly injection, is indicated for the maintenance treatment of 
schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly 
paliperidone palmitate injectable products (see section 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 Formerly Paliperidone Janssen-Cilag International 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
  
 
 
